Advertisement
Advertisement

LENZ

LENZ logo

LENZ Therapeutics, Inc. Common Stock

6.15
USD
Sponsored
-0.19
-3.00%
Jun 18, 16:00 UTC -4
Closed
exchange

After-Market

6.09

-0.06
-0.98%

LENZ Earnings Reports

Positive Surprise Ratio

LENZ beat 9 of 20 last estimates.

45%

Next Report

Date of Next Report
Jul 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.54M
/
-$1.09
Implied change from Q1 26 (Revenue/ EPS)
+33.85%
/
-17.42%
Implied change from Q2 25 (Revenue/ EPS)
-49.11%
/
+113.73%

LENZ Therapeutics, Inc. Common Stock earnings per share and revenue

On May 11, 2026, LENZ reported earnings of -1.32 USD per share (EPS) for Q1 26, missing the estimate of -1.09 USD, resulting in a -21.05% surprise. Revenue reached 1.90 million, compared to an expected 1.67 million, with a 14.11% difference. The market reacted with a -20.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -1.09 USD, with revenue projected to reach 2.54 million USD, implying an decrease of -17.42% EPS, and increase of 33.85% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, LENZ Therapeutics, Inc. Common Stock reported EPS of -$1.32, missing estimates by -21.05%, and revenue of $1.90M, 14.11% above expectations.
The stock price moved down -20.82%, changed from $9.99 before the earnings release to $7.91 the day after.
The next earning report is scheduled for Jul 28, 2026.
Based on 5 analysts, LENZ Therapeutics, Inc. Common Stock is expected to report EPS of -$1.09 and revenue of $2.54M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement